<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="disease. 17 Less commonly, there may also be elevations in" exact="alanine" post="aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK) and"/>
 <result pre="also be elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST)," exact="creatine" post="kinase (CK) and Dâ€�dimer.17 Recommendations on whom to test"/>
 <result pre="Risk of respiratory tract infections Risk of serious infections Steroids" exact="Prednisolone" post="URTI for influenza compared to placebo OR 1.22 (95%"/>
 <result pre="compared to placebo69 OR 3.32 (95% CI 0.13â€�84.9) compared to" exact="prednisolone" post="69 Immunomodulators Thiopurines 2.1 per patientâ€�years70 OR 0.143 (95%"/>
 <result pre="per patientâ€�years70 OR 0.143 (95% CI 0.43â€�4.76) compared to placebo70" exact="Methotrexate" post="OR 1.02 (95% 0.88â€�1.19)73 compared with placebo OR 0.52"/>
 <result pre="and increase the risk of COVIDâ€�19 exposure and infection. 4.1" exact="Sulfasalazine" post="and 5â€�aminosalicylates (5â€�ASAs) Sulfasalazine and the 5â€�ASA medications are"/>
 <result pre="of COVIDâ€�19 exposure and infection. 4.1 Sulfasalazine and 5â€�aminosalicylates (5â€�ASAs)" exact="Sulfasalazine" post="and the 5â€�ASA medications are used as firstâ€�line induction"/>
 <result pre="not demonstrate an increased risk of serious or opportunistic infections.53" exact="Sulfasalazine" post="and 5â€�ASA Treatment with 5â€�ASA therapy should continue without"/>
 <result pre="hospitalisation and mortality in IBD patients, particularly at doses of" exact="prednisolone" post="or its equivalent â‰¥20Â mg.61, 62, 63, 64 Therefore,"/>
 <result pre="placebo.65, 66, 67, 68, 69 Corticosteroids Corticosteroids (particularly â‰¥20Â mg" exact="prednisolone" post="or its equivalent) are associated with an increased risk"/>
 <result pre="upper respiratory tract infections or pulmonary infections.70, 71 In addition," exact="mercaptopurine" post="has been shown to inhibit one of the proteases"/>
 <result pre="although no further animalâ€�based models exist to suggest clinical efficacy.72" exact="Methotrexate" post="has variably been demonstrated to increase the risk of"/>
 <result pre="population, there was not an increased risk of infection with" exact="methotrexate" post="(1.03, 95% CI0.82â€�1.3).73 This applied similarly to respiratory infections"/>
 <result pre="of antiâ€�TNFs.90 Serious infection was found to be increased with" exact="tofacitinib" post="in the induction trials for UC, but similar across"/>
 <result pre="placebo in the maintenance trial.91 Of 4789 patients treated with" exact="tofacitinib" post="in phase II, III and LTE studies, 259 patients"/>
 <result pre="associated with increased serious infection risk.92, 93 Therefore, patients on" exact="tofacitinib" post="should be maintained on the lower 5Â mg twice"/>
 <result pre="daily as opposed to 10Â mg twice daily. Avoid commencing" exact="tofacitinib" post="during pandemic unless there are no other alternatives. This"/>
 <result pre="is in contact with someone with COVIDâ€�19, consider temporarily withholding" exact="tofacitinib" post="for 2Â weeks. If a patient tests positive for"/>
 <result pre="patient tests positive for SARSâ€�CoVâ€�2 and/or develops COVIDâ€�19, consider withholding" exact="tofacitinib" post="until patient clears the infection. 4.6 Recommencement of medications"/>
 <result pre="hours. Pharmacodynamic effects generally reversible in 14Â days after discontinuation" exact="Methotrexate" post="Methotrexate in serum has a halfâ€�life of 6Â hours"/>
 <result pre="Pharmacodynamic effects generally reversible in 14Â days after discontinuation Methotrexate" exact="Methotrexate" post="in serum has a halfâ€�life of 6Â hours but"/>
 <result pre="a halfâ€�life of 6Â hours but is converted quickly to" exact="methotrexate" post="polyglutamate which is stored for much longer in liver"/>
 <result pre="and erythrocytes.132 3â€�10Â hours (for methotrexate, not activity) 75% of" exact="methotrexate" post="eliminated by within 24Â hours but effect continues through"/>
 <result pre="with soap and water for 20Â seconds or use an" exact="alcohol" post="rub, practice social distancing by working from home, standing"/>
 <result pre="to limit nonâ€�urgent pathology requests and avoid commencing thiopurines or" exact="tofacitinib" post="that require frequent blood monitoring early on. Finally, elective"/>
 <result pre="and CYP2B6 â€�unlikely clinically significant All in vitro data Lopinavir/" exact="Ritonavir" post="(Kaltera) (400Â mg/100Â mg) 400mg/100mg twice daily for 14"/>
 <result pre="Crushing tablet â†&quot; absorption â‰… 45%133. Use oral liquid (42.4%" exact="alcohol" post="and 15.3% propylene glycol) Use compatible feeding tubes (PVC"/>
 <result pre="propylene glycol) Use compatible feeding tubes (PVC or silicone) Avoid" exact="metronidazole" post="and disulfiram Absorbed in jejunum: NG ok; NJ may"/>
 <result pre="Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and" exact="disulfiram" post="Absorbed in jejunum: NG ok; NJ may â†&quot; effect"/>
 <result pre="â€�care with narrow therapeutic index drugs dependent on CYP450 clearance" exact="Ribavirin" post="Do not crush â€&quot;known teratogen. Contact hospital pharmacy for"/>
 <result pre="to CYP interactions. Inhibits inosine monophosphate dehydrogenase: Can interfere with" exact="azathioprine" post="metabolism possibly leading to accumulation of 6â€�methylthioinosine monophosphate (6â€�MTIMP),"/>
 <result pre="plus interferonâ€�Î± ChiCTR2000029544 favipiravir plus baloxavir marboxil Metabolised by: Nicotinamide" exact="adenine" post="dinucleotide phosphate (NADPH) independent and dependent enzymes. Inhibits: CYP2C8"/>
 <result pre="CYP1A2(weak), CYP2C9(weak), CYP2C19(weak), CYP2CD6(weak), CYP2E1(weak), CYP3A4(weak) Low risk QT prolongation" exact="Atazanavir" post="Requires pH &amp;lt;4. Avoid antacids 2Â h before and"/>
 <result pre="Absorption depends on low pH; drugs increasing pH will decrease" exact="atazanavir" post="concentration Dose related prolongation in PR interval. Care with"/>
 <result pre="clinically relevant Thiopurines (azathioprine/ mercaptopurine) Metabolised by: TMPT, HGPRT, XO" exact="Methotrexate" post="Transported into the cell by: Reduced folate carrier 1"/>
 <result pre="TMPT, HGPRT, XO Methotrexate Transported into the cell by: Reduced" exact="folate" post="carrier 1 Tacrolimus Inhibits: CYP3A4 (weak) Metabolised by CYP3A4"/>
 <result pre="Methotrexate Transported into the cell by: Reduced folate carrier 1" exact="Tacrolimus" post="Inhibits: CYP3A4 (weak) Metabolised by CYP3A4 Ciclosporin Metabolised by"/>
 <result pre="Crushing tablet â†&quot; absorption â‰… 45%133. Use oral liquid (42.4%" exact="alcohol" post="and 15.3% propylene glycol) Use compatible feeding tubes (PVC"/>
 <result pre="propylene glycol) Use compatible feeding tubes (PVC or silicone) Avoid" exact="metronidazole" post="and disulfiram Absorbed in jejunum: NG ok; NJ may"/>
 <result pre="Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and" exact="disulfiram" post="Absorbed in jejunum: NG ok; NJ may â†&quot; effect"/>
 <result pre="Methylprednisolone: Consider 50% dose reduction 124. â†‘ Prednisolone: â†&quot; plasma" exact="cortisol" post="(level if appropriate) â†‘ Budesonide: 10â€�20% absorbed134. AUC may"/>
 <result pre="low bioavailability, increased absorption may occur, monitor for effect69 â†‘" exact="Tacrolimus" post="levels: perform levels, consider clinical need and cease â†‘"/>
 <result pre="consider clinical need and cease. If necessary, use lowest dose" exact="tofacitinib" post="possible Chloroquine / Hydroxychloroquine 200Â mg three times a"/>
 <result pre="need and cease. If necessary, use lowest dose tofacitinib possible" exact="Chloroquine" post="/ Hydroxychloroquine 200Â mg three times a day for"/>
 <result pre="cease. If necessary, use lowest dose tofacitinib possible Chloroquine /" exact="Hydroxychloroquine" post="200Â mg three times a day for 10 days"/>
 <result pre="thiopurine in acute severe infection â†‘ myelosuppression risk. Recommend ceasing" exact="methotrexate" post="in acute severe infection â†‘ risk of QTâ€�interval prolongation."/>
 <result pre="of QTâ€�interval prolongation. consider baseline and follow up ECG â†‘" exact="ciclosporin" post="levels, perform levels if appropriate May â†‘ tofacitinib, clinical"/>
 <result pre="May â†‘ corticosteroid levels, clinical significance unknown, monitor. May â†‘" exact="ciclosporin" post="levels, clinical significance unknown, monitor levels May â†‘ tofacitinib,"/>
 <result pre="tofacitinib, clinical significance unknown, monitor. Consider lower dose where appropriate" exact="Ribavirin" post="Do not crush â€&quot;known teratogen. Contact hospital pharmacy for"/>
 <result pre="of thiopurine induced myelosuppression Cease thiopurine â†‘ risk myelosuppression Cease" exact="methotrexate" post="Favipiravir Atazanavir Requires pH &amp;lt;4. Avoid antacids 2 hours"/>
 <result pre="induced myelosuppression Cease thiopurine â†‘ risk myelosuppression Cease methotrexate Favipiravir" exact="Atazanavir" post="Requires pH &amp;lt;4. Avoid antacids 2 hours before and"/>
 <result pre="Methylprednisolone: Consider 50% dose reduction 124. â†‘ Prednisolone: â†&quot; plasma" exact="cortisol" post="(level if appropriate) â†‘ Budesonide: 10â€�20% absorbed134. AUC may"/>
 <result pre="low bioavailability, increased absorption may occur, monitor for effect69 â†‘" exact="ciclosporin" post="and â†‘ atazanavir. Do not coâ€�administer. â†‘ tofacitinib, recommend"/>
 <result pre="and â†‘ atazanavir. Do not coâ€�administer. â†‘ tofacitinib, recommend ceasing" exact="tofacitinib" post="Nitazoxanide (prodrug) (active metabolite: tizoxanide) May be dispersible or"/>
 <result pre="emergency. 6.1 Remdesivir (GSâ€�5734) Remdesivir is a prodrug of the" exact="adenosine" post="nucleotide analogue GSâ€�441524 that incorporates into nascent viral RNA"/>
 <result pre="combines two protease inhibitors, the latter used to pharmacokinetically â€˜boostâ€™" exact="lopinavir" post="concentrations and prolong the effect through CYP3A4 inhibition.104 Licensed"/>
 <result pre="medication regime. Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus," exact="ciclosporin" post="and tofacitinib which may lead to toxicity (TableÂ 4)."/>
 <result pre="Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus, ciclosporin and" exact="tofacitinib" post="which may lead to toxicity (TableÂ 4). 6.3 Chloroquine"/>
 <result pre="and tofacitinib which may lead to toxicity (TableÂ 4). 6.3" exact="Chloroquine" post="or hydroxychloroquine Chloroquine is a widely used antiâ€�malarial and"/>
 <result pre="which may lead to toxicity (TableÂ 4). 6.3 Chloroquine or" exact="hydroxychloroquine" post="Chloroquine is a widely used antiâ€�malarial and autoimmune disease"/>
 <result pre="may lead to toxicity (TableÂ 4). 6.3 Chloroquine or hydroxychloroquine" exact="Chloroquine" post="is a widely used antiâ€�malarial and autoimmune disease drug."/>
 <result pre="antiâ€�viral effect and reduce COVIDâ€�19 complications synergistically.108 Compared to controls," exact="chloroquine" post="had a superior effect in 100 patients in China"/>
 <result pre="of pneumonia, duration of symptoms and delay in viral clearance.109" exact="Chloroquine" post="is not accessible in Australia and it has been"/>
 <result pre="not accessible in Australia and it has been suggested that" exact="hydroxychloroquine" post="could be an effective alternative given that it is"/>
 <result pre="effective alternative given that it is an identical molecule to" exact="chloroquine" post="apart from the addition of a hydroxyl group. 108,"/>
 <result pre="study, 20 COVIDâ€�19 positive patients (&amp;gt;12Â years of age) received" exact="hydroxychloroquine" post="200Â mg three times a day for 10Â days"/>
 <result pre="At day 6, virological clearance was 57% in those receiving" exact="hydroxychloroquine" post="compared with 12.5% in the control group (PÂ =Â"/>
 <result pre="patients who were transferred to ICU. Furthermore, the combination of" exact="azithromycin" post="and hydroxychloroquine should be considered with caution given additive"/>
 <result pre="were transferred to ICU. Furthermore, the combination of azithromycin and" exact="hydroxychloroquine" post="should be considered with caution given additive potential of"/>
 <result pre="fees from Abbvie, personal fees from Abgenomics, personal fees from" exact="Allergan" post="Inc, personal fees from Boehringer Ingelheim Ltd, personal fees"/>
 <result pre="et al. Quantitative proteomic analysis reveals the deregulation of nicotinamide" exact="adenine" post="dinucleotide metabolism and CD38 in inflammatory bowel disease. Biomed"/>
 <result pre="respiratory syndrome: the impact of high dosage and duration of" exact="methylprednisolone" post="therapy. Zhonghua Nei Ke Za Zhi. 2004;43:179â€&quot;182.15059370 60LiY. Relationship"/>
 <result pre="MangusoF, ZibelliniM, et al. Oral prolonged release beclomethasone dipropionate and" exact="prednisone" post="in the treatment of active ulcerative colitis: results from"/>
 <result pre="Ther. 2009;29:1106â€&quot;1113.19222411 72ChengKâ€�W, ChengSâ€�C, ChenWâ€�Y, et al. Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papainâ€�like protease of Middle East respiratory"/>
 <result pre="Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ. Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and metaâ€�analysis."/>
 <result pre="metaâ€�analysis. J Clin Med. 2019;8:15. 74ConwayR, LowC, CoughlanRJ, et al." exact="Methotrexate" post="use and risk of lung disease in psoriasis, psoriatic"/>
 <result pre="2018;24:2258â€&quot;2265.29850873 90WollenhauptJ, LeeEB, CurtisJR, et al. Safety and efficacy of" exact="tofacitinib" post="for up to 9.5 years in the treatment of"/>
 <result pre="1):i34â€&quot;i42.30806708 93WeisshofR, Aharoni GolanM, SossenheimerPH, et al. Realâ€�world experience with" exact="tofacitinib" post="in IBD at a Tertiary Center. Dig Dis Sci."/>
 <result pre="exoribonuclease. mBio. 2018;9. 103WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
 <result pre="RolainJâ€�M, ColsonP, RaoultD. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVIDâ€�19?Int J Antimicrob"/>
 <result pre="COVIDâ€�19?Int J Antimicrob Agents. 2020. 109ColsonP, RolainJâ€�M, LagierJâ€�C, et al." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVIDâ€�19. Int"/>
 <result pre="Antimicrob Agents. 2020. 109ColsonP, RolainJâ€�M, LagierJâ€�C, et al. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVIDâ€�19. Int J Antimicrob"/>
 <result pre="fight COVIDâ€�19. Int J Antimicrob Agents. 2020;105932. 110ColsonP, RolainJM, RaoultD." exact="Chloroquine" post="for the 2019 novel coronavirus SARSâ€�CoVâ€�2. Int J Antimicrob"/>
 <result pre="Int J Antimicrob Agents. 2020;55:105923.32070753 111GautretP, LagierJâ€�C, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
 <result pre="Antimicrob Agents. 2020;55:105923.32070753 111GautretP, LagierJâ€�C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
 <result pre="to view. 123CohenSB, TanakaY, MarietteX, et al. Longâ€�term safety of" exact="tofacitinib" post="for the treatment of rheumatoid arthritis up to 8.5"/>
 <result pre="Clin Pharmacokinet. 2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP, CaraC, RodrigoL. Comparative effectiveness of" exact="azathioprine" post="in Crohn's disease and ulcerative colitis: prospective, longâ€�term, followâ€�up"/>
</results>
